Adverse effects (number of participants who had the event) · People with American cutaneous and mucocutaneous leishmaniasis
Oral miltefosine (1.2 to 3.3 mg/kg/d 28 days) probably leads to higher adverse effects (number of participants who had the event) compared with meglumine antimoniate (20 mg/kg 20 days) (moderate certainty).
1 finding from 1 review
Recurrence ‐ not measured · People with American cutaneous and mucocutaneous leishmaniasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Infectious complications · people undergoing gastrointestinal surgery
Immune‐enhancing supplements (oral or enteral) showed no clear difference in infectious complications recorded up to 30 days postdischarge compared with usual care or control (low certainty).
1 finding from 1 review
Length of hospital stay · people undergoing gastrointestinal surgery
1 finding from 1 review
Adverse effects · people undergoing gastrointestinal surgery
1 finding from 1 review
Non‐infectious complications · people undergoing gastrointestinal surgery
Immune‐enhancing supplements (oral or enteral) showed no clear difference in non‐ infectious complications recorded up to 30 days postdischarge compared with usual care or control (low certainty).
1 finding from 1 review
BMD: % change in BMD at the lumbar spine · children under the age of 18 with cerebral palsy (GMFCS levels III to V)
1 finding from 1 review
Change in volumetric BMD of distal radius or tibia · children under the age of 18 with cerebral palsy (GMFCS levels III to V)
1 finding from 1 review
Change in fracture frequency · children under the age of 18 with cerebral palsy (GMFCS levels III to V)
1 finding from 1 review
Number of participants reporting an adverse event · children under the age of 18 with cerebral palsy (GMFCS levels III to V)
1 finding from 1 review
Change in NTX (assessed 4 to 6 months post‐intervention) · children under the age of 18 with cerebral palsy (GMFCS levels III to V)
1 finding from 1 review
Change in BAP (assessed 4 to 6 months post‐intervention) · children under the age of 18 with cerebral palsy (GMFCS levels III to V)
1 finding from 1 review
Peritonitis · chronic peritoneal dialysis patients
Oral or topical or intraperitoneal antibiotics showed no clear difference in peritonitis (number of patients with one or more episodes) compared with placebo/no treatment (low certainty).
1 finding from 1 review
Exit‐site/tunnel infection · chronic peritoneal dialysis patients
Oral or topical or intraperitoneal antibiotics showed no clear difference in exit‐site/tunnel infection (number of patients with one or more… compared with placebo/no treatment (low certainty).
1 finding from 1 review
Catheter removal or replacement · chronic peritoneal dialysis patients
Oral or topical or intraperitoneal antibiotics showed no clear difference in catheter removal or replacement (number of patients) compared with placebo/no treatment (low certainty).
1 finding from 1 review
Change in dry eye symptoms, measured using the OSDI score (ranging from 0 to 100 units, with a reduction in score indicating clinical improvement) at 1‐month (with actual · people with dry eyea
Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) showed no clear difference in change in dry eye symptoms, measured using the OSDI score (ranging… compared with placebo or no treatment (low certainty).
1 finding from 1 review
Change in ocular surface staining at 1‐month (with actual · people with dry eyea
Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) showed no clear difference in change in ocular surface staining at 1‐month (with actual compared with placebo or no treatment (low certainty).
1 finding from 1 review
Aqueous tear production · people with dry eyea
Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) showed no clear difference in change in Schirmer test (aqueous tear production, measured in mm/5… compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Tear film stability · people with dry eyea
1 finding from 1 review
Change in tear osmolarity (measured in mOsmol/L, with reductions in osmolarity indicating clinical improvement) at 1‐month (with actual · people with dry eyea
Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) showed no clear difference in change in tear osmolarity (measured in mOsmol/L, with reductions in… compared with placebo or no treatment (low certainty).
1 finding from 1 review